Drug Profile


Alternative Names: BVF-018; Choreazine Tablets 12.5mg; Nitoman; Xenazina; Xenazine; Xenazine 25

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LifeHealth Limited
  • Developer AFT Pharmaceuticals; Alfresa Pharma Corporation; ApotheekZorg; Cambridge Laboratories; Chiesi Farmaceutici; EUSA Pharma; Lundbeck A/S; Medilink Pharmaceuticals; Orphan Australia; Temmler Pharma; UCB; Valeant Canada
  • Class Antipsychotics; Quinolizines; Small molecules
  • Mechanism of Action Dopamine receptor antagonists; Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease; Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Drug-induced dyskinesia; Huntington's disease; Movement disorders
  • Discontinued Gilles de la Tourette's syndrome

Most Recent Events

  • 30 May 2013 Biomarkers information updated
  • 12 Jun 2012 EUSA Pharma has been acquired by Jazz Pharmaceuticals plc
  • 28 Sep 2010 Biovail Corporation merged with Valeant Pharmaceuticals International forming Valeant Pharmaceuticals International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top